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Abstract
Objectives The objectives were to investigate the impact of ‘time-effect’ on the estima-
tion of quality-adjusted life years (QALYs) along prospective clinical trials’ outcomes
using an assumed ﬁxed time duration versus the actual time durations for each case. The
‘time’ duration is the length of time in a health state.
Methods Two methods were used in the estimation of QALYs based using EQ-5D 3L
scores collected at speciﬁc time-point intervals. One method used the actual time dura-
tions for each case based on CRF records, and the other used an assumed time duration
and globally applied it to all the cases. Using SPSS software program, we used paired-
sample t-tests to assess whether the ‘time-effect’ can potentially affect trial results using
CONSTRUCT trial data as reported in the trial results publications. The trial compared
use of Inﬂiximab with Cyclosporine for patients with Ulcerative Colitis and it involved
some 270 participants.
Key findings The results largely indicate statistically signiﬁcant differences between the
two methods of QALY estimations. QALYs at the respective time-points indicate no sta-
tistical difference between the two approaches. However, the difference in terms of total
QALYs between the two QALY estimation approaches is statistically signiﬁcant with
considerable impact on costs/QALY.
Conclusions Considering the possible impact of the time-effect on QALY estimations,
the result implies that it can have signiﬁcant implications for resources allocations deci-
sions. In this respect, researchers have to pay due considerations to the approach they use
and where possible, actual time durations must be used in QALY estimations along
prospective clinical trials.
Keywords health economics; outcome research; patient satisfaction; quality-adjusted life
years
Introduction
EQ-5D-3L is a generic preference-based patient-reported outcome measure which can be
used to provide estimations of quality-adjusted life years (QALYs) gained. QALYs is a
measure of quality and quantity of life (i.e. a product of the health-related utility state
and the number of times or period in that state). Estimations of QALYs from EQ-5D util-
ity scores collected at different time-points along clinical trials can be made using two
approaches. The two approaches are the application of the same ﬁxed period of time
between visits for all participants, for example 3 months (converted to years), if data
were supposed to be collected at 3-month interval for participants or using the actual per-
iod between visits using the actual dates when the EQ-5D-3L data were collected as
recorded on Case Report Forms (CRFs) or Patient Follow-up Questionnaires (PFQs) in
the estimation of QALYs. In the second method, the time period would be the difference
between the recorded dates on the CRFs or PFQs. For example, the period/time (in years)
between two time-points for CRFs/PFQs with dates 05/10/2012 and 21/01/2013 would be
0.29589 assuming 1 year to be 365 days.
The objective of this study was to evaluate the possible impacts of the two methods
of QALY estimation along clinical trials on the trial results using patient-level data from
the CONSTRUCT clinical trial. The null hypothesis for this research is that there is no
statistically signiﬁcant difference of means between total QALYs for the ﬁxed-period
method and the non-ﬁxed-period approaches (i.e. the one for which the periods or time
factors for QALY calculations are based on actual EQ-5D dates as provided on the CRFs
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and PFQs). While total QALYs are the main outcome of
interest for this study, differences between the two
approaches for QALYs at the respective data collection
points are also examined.
The CONSTRUCT trial was a non-blinded controlled
study which compared Inﬂiximab with Cyclosporine for
patients with Ulcerative Colitis.[1] Inﬂiximab and Cyclospor-
ine are among few immunosuppressive drugs which are pre-
dominantly in use for treatment of steroid-resistant
Ulcerative Colitis.[1,2] The trial was funded by National
Institute for Health Technology Assessment Programme and
conducted by the College of Medicine, Swansea University.
The economic evaluation component was subcontracted to
the Health Economics and Policy Research Unit, University
of South Wales. The protocol and the results of the trial
have been reported by Seagrove et al.[1] and Williams
et al.[3,4] respectively.
Methods
Comprehensive description of the trial design has been pro-
vided in Seagrove et al. paper. Figure 1 provides the ﬂow
chart of the clinical trial.
Participants were randomly allocated to either Inﬂiximab
or Cyclosporine in equal proportions. In all, 52 UK centres
(including large teaching hospitals) across various NHS
Health Boards or Trusts in Wales, England and Scotland,
participated in the study.[1]
The main clinical outcomes (results of which have been
reported by Williams et al.[3,4] include mortality, colec-
tomies, readmissions, quality of life and cost-effectiveness
of the interventions. Data on these measures were collected
from participants at baseline, 3, 6, 12, 18, 24, 30 and
36 months. The target population were patients with acute
severe Ulcerative Colitis who failed to respond to 2–5 days
Figure 1 CONSTRUCT trial ﬂow chart adopted from trial protocol (Seagrove et al.[1]).
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course of intravenous steroid treatment and did not need
surgery. Of the 270 randomised to the clinical trial 100
were female and 250 being White.[3,4] The mean weight and
height were 74.14 kg and 1.71 m respectively. One hundred
and twelve indicated that they have never smoked.[3,4]
The quality of life outcomes were measured using EQ-
5D-3L, CUCQ and SF-6D. The EQ-5D-3L health state val-
ues were used in the estimation of QALYs. The quality of
life instruments were completed by participants at speciﬁc
time intervals cited earlier.[1] These intervals (or data collec-
tion time-points) are key components in the estimation of
QALYs.
The estimation of QALYs adopted a linear approach
based on Manca et al.[5] as in the formula below.
Total QALYs
¼ x1 þ x2
2
 p1þ x2þ x32  p2 þ
x3þ x4
2
 p3 þ x4þ x52  p4
where xi represents EQ-5D-3L utility scores at respective data
collection points and pi, the periods between the EQ-5D-3L
utility scores for the respective data collection points. This
assumes a linear relationship between data collection time-
points and can be described as the area under the straight
lines. The periods between visits can be calculated using
patient-level data using the dates recorded on the respective
CRFs and PFQs (i.e. on the completed EQ-5D-3L forms).
In the application of this formula, two methods were
used. One was the use of the same equal periods of time
between data collection points of baseline, 3, 6, 12 months
and the like across for all cases as applicable, and the other
is the use of actual dates (reﬂecting when the scores were
provided) on the questionnaires to calculate the time periods
in the estimation of QALYs.
Where there were cases of missing data for EQ-5D-3L
utility values, data for the last/previous known state are
used consistent with White et al. (2011).[6] Participants lost
to follow-up for any particular reason including deaths and
withdrawals were not included in EQ-5D utility analyses.
Participants with only one EQ-5D records were as well not
included in any estimation of QALYs.
In the case of missing dates, if it is between two data
collection points, the mid-point between the dates is used. If
it is at the end, for example when we have dates for the 30-
months’ data collection point but not for the 36-months’
collection point, then 182 days which is supposed to be the
period in days between the 30th and 36th months is added
to compute the missing date. If a date is provided but not
EQ-5D-3L utility value, then it is treated as a missing value.
Where two EQ-5D-3L questionnaires are recorded for a par-
ticipant and the period between them, span over many data
collection points then the intervening data collection points
is treated as missing and not as if the participant has only
two EQ-5D utility values.
As this study is intended to highlight essential method-
ological issues in the calculation of QALYs along clinical
trials, it will not be reporting or commenting on the ﬁnal
results of the CONSTRUCT trial. Central to the analyses
for this research is ‘total QALYs’ in the two QALY estima-
tion approaches (i.e. using ﬁxed and non-ﬁxed time periods
in the estimation of QALYs). In these, both discounted and
non-discounted total QALYs were examined. A discount
rate of 3% was used. Even though total QALYs are the
main outcome of interest for the comparison of the two
approaches, QALYs at the respective data collection points,
that is, at 3, 6, 12, 18, 24, 30 and 36 months using the two
approaches were analysed as well. Paired-sample t-test was
used to compare the two approaches with and without boot-
strapping using total QALYs.
To test the statistical difference between two measure-
ments that are from the same sample, paired-sample t-tests
also known as repeated measures t-tests were performed.
Prior to conducting this test, the data were examined to
ensure that all the essential conditions for the test, such as
assumptions of normality, issues of outliers and the depen-
dent variable to be a continuous data among others, are
met. Had these conditions not been met it would have been
appropriate to use Wilcoxon signed-ranks test instead,
which is a nonparametric test used where data are not
assumed to be normally distributed.
Paired-sample t-tests were performed on both QALYs esti-
mated at the respective data collection time-points, and the
main outcome of interest which is total QALYs (discounted
and non-discounted) estimated using the two approaches
being investigated. These are use of ﬁxed time periods and
patient-level data dates in the calculation of QALYs. Total
QALYs are the main outcome of interest for reasons that it is
the total QALYs that determine the ﬁnal HRQoL results of a
clinical trial and therefore feed into UK’s National Institute of
Health and Care Excellence’s (NICE) threshold considera-
tions for the use of a drug or otherwise in the National Health
Service. Bootstrapping was also used to assess whether differ-
ences between the two approaches will continue to be signiﬁ-
cant even with resampling or data replication.
All the analyses were performed using SPSS of IBM
Corporations, Armonk, NY, USA. The mapping of EQ-5D-
3L scores to utility values was performed using SPSS.
The same program was used to organise the data as well as
for the handling of missing data.
Results
In all, 270 participants with acute severe Ulcerative Colitis
who failed to respond to intravenous steroid and did not
need surgery were randomised to participate in the two-arm
non-blinded clinical trial. Of this, 12 participants withdrew
consent for both CRF and PFQ and were therefore not
included in any of the analyses in any way or form hence
258 participants remained for inclusion in the analyses.
Table 1 provides details of the number of available EQ-5D-
3L data used in the estimation of QALYs at the respective
data collection points.
Paired-sample t-tests
The analyses of QALYs for the various data collection
time-points largely indicate no signiﬁcant differences
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between the two methods at the respective time-points
(Table 2). The only place where there is signiﬁcant differ-
ence is at 6th Months’ time-point where the 2-tailed signiﬁ-
cant P-value is 0.005.
With regard to the main outcome of interest, total
QALYs, there is statistically signiﬁcant difference between
the two QALY calculation approaches. Even after conduct-
ing bootstrapping, the 2-tailed signiﬁcance P-values on the
differences between the two approaches remained signiﬁcant
for both discounted and non-discounted total QALYs. The
bootstrapping results are based on 10 000 bootstrap sam-
ples. Table 3 provides details on the results of paired-sam-
ple tests on total QALYs for the two methods. These results
demonstrate the potential impact of ‘time-effect’ on the out-
come of QALY estimations along clinical trials for EQ-5D
scores collected at different time-points.
The cost-effectiveness analysis in Williams et al.[3,4]
indicated mean cost per QALY to be £7604.89 and
£10 664.38 for Cyclosporine and Inﬂiximab, respectively,
over 30-month period. These costs were weighted by partic-
ipants’ time in the clinical trial. As this study covers a per-
iod of 36 months, we have made the assumption that above
costs over 30 months should not signiﬁcantly change in the
additional 6-month period. In this respect, applying the
above mean costs would result in cost-effectiveness ratio of
£93504.09/QALY using actual time period approach in cal-
culation of QALYs. When the ﬁxed-period approach is
used, the cost-effectiveness ratio has been increased to
£119575.83/QALY in favour of Cyclosporine.
Discussions
Based on the results, the paper emphasises the need for
researchers to report the approach they employed in their
estimation of QALYs from EQ-5D utility data collected at
different time-points along clinical trials due to its possible
implications on trial results. These results have consistently
indicated signiﬁcant differences between the outcomes of
the two approaches even with data replication. The applica-
tion of the mean costs to these results also indicates stark
differences between the two approaches.
Patient-reported outcome measures (PROMs) proved to
be vital in providing yardsticks in many areas of healthcare
delivery around the world. While there can be many reasons
for this, the main thing is that it is because patients
Table 1 EQ5D data available at various collection points for
estimation of QALYs
Frequency Percentage
EQ5D@3M Not included 25 9.3
Included 224 83.0
Not include_1_EQ5D 21 7.8
Total 270 100.0
EQ5D@6M Not included 25 9.3
Included 224 83.0
Not include_1_EQ5D 21 7.8
Total 270 100.0
EQ5D@12M Not included 29 10.7
Included 220 81.5
Not include_1_EQ5D 21 7.8
Total 270 100.0
EQ5D@18M Not included 74 27.4
Included 175 64.8
Not include_1_EQ5D 21 7.8
Total 270 100.0
EQ5D@24M Not included 130 48.1
Included 119 44.1
Not include_1_EQ5D 21 7.8
Total 270 100.0
EQ5D@30M Not included 177 65.6
Included 72 26.7
Not include_1_EQ5D 21 7.8
Total 270 100.0
EQ5D@36 Not included 237 87.8
Included 33 12.2
Total 270 100.0
QALYs, quality-adjusted life years.
Table 2 Paired-sample t-tests for quality-adjusted life years (QALYs) for the respective data collection points
Paired samples test
N Paired differences t df Sig.
(2-tailed)
Mean Std.
deviation
Std.
error
mean
95% conﬁdence
interval of the
difference
Lower Upper
Pair 1 QALY_3M – QALY_3M_Fixed 224 0.0030837 0.0379836 0.0025379 0.0019176 0.0080850 1.215 223 0.226
Pair 2 QALY_6M – QALY_6M_Fixed 224 0.0106664 0.0562696 0.0037597 0.0032573 0.0180754 2.837 223 0.005
Pair 3 QALY_12M – QALY_12M_Fixed 220 0.0026320 0.0856848 0.0057769 0.0087534 0.0140173 0.456 219 0.649
Pair 4 QALY_18M – QALY_18M_Fixed 175 0.0008077 0.0687918 0.0052002 0.0094559 0.0110712 0.155 174 0.877
Pair 5 QALY_24M – QALY_24M_Fixed 119 0.0145399 0.0991509 0.0090892 0.0034591 0.0325389 1.600 118 0.112
Pair 6 QALY_30M – QALY_30M_Fixed 72 0.0031073 0.0916555 0.0108017 0.0246453 0.0184307 0.288 71 0.774
Pair 7 QALY_36M – QALY_36M_Fixed 33 0.0092164 0.1071548 0.0186532 0.0472118 0.0287790 0.494 32 0.625
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themselves provide the information. In this light, PROMs
provide validated evidences of health from the patients’
point of view hence can be used to assess health needs and
levels in populations particularly the users of healthcare
services. PROMs can therefore serve as evidences of the
impact and outcomes of healthcare interventions and services.
EQ-5D is one of the non-disease-speciﬁc measurements
(generic instruments) used in this research, which feeds into
HRQoL measures used by researchers and decision makers
for healthcare analysis and resources allocations amongst
others. In the context of the United Kingdom, EQ-5D is
one of those preference-based measurements used in the
estimation of QALYs, which is mathematically a product of
the health utility and the time spent in that health utility.
QALYs are key yardsticks in health economic decisions
regarding the introduction of healthcare interventions into
the National Health Service.
The implications of these current research results with
respect to the differences between the two QALY calcula-
tion approaches along clinical trials and for that matter the
potential impact of ‘time-effect’ on total QALY outcome
can be essential for many reasons. First, EQ-5D scores
reported by a patient are not a retrospective reﬂection of the
person’s health state but the health state at the ‘time’. So
using a different date and for that matter ‘time’ is a misrep-
resentation of realities. Second, in real-life situations,
patients should not be expected to be reporting at exactly
the same time intervals. In addition to appointment failures,
there are also variations in terms of waiting time across
practices. Third, studies that may not have the time and
resources to conduct RCTs, such as those using meta-analy-
sis, may be using mean total QALY results of these types
of trials to feed into their research. The outcomes of clinical
trials can therefore greatly inﬂuence the results of such
meta-analyses studies. Fourth, as indicated in the costing
and cost-effectiveness projections, it is clear that it can have
resources allocation decision implications. The increment in
terms of cost-effectiveness ratios between the two
approaches is well over 20% which can be fundamental
considering limited healthcare resources challenges.
This analysis has a number of limitations. The sample
size can be considered to be too small. Because of the small
sample size bootstrapping was used which is a standard
practice in economic evaluation analysis conducted along-
side clinical trials.[7–10] As a result of the small sample size,
the mean difference in terms of days between the two
approaches is about 8 days. However, 8 days can have
enormous healthcare resources implications as demonstrated
in the economic evaluation projections. The missing data
imputation approaches used in Williams et al.[3,4] and this
study differ. This explains the differences in terms of num-
bers (for the respective data collection points) and QALYs
gained in the descriptive analysis of this study and that of
Williams et al.[3,4]
Differences between QALY totals at most of the data
collection points are not statistically signiﬁcant (see table).
However, the hypothesis for this analysis is premised on the
overall QALYs’ total and not that of the respective data col-
lection points. It is not these individual QALYs at the speci-
ﬁc data collection points along a prospective trial whichTa
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represent the ﬁnal QALY outcome. It is instead the total
QALYs (which is the sum of the QALYs estimated at the
various time-points).
Considering the statistically signiﬁcant differences
between the two methods as revealed by this current analy-
sis, it is imperative and essential for researchers to report
which of the two approaches they employed in the estima-
tion of QALYs from preference-based utilities collected at
different time-points along clinical trials. It is also vital that
they report conﬁdence intervals for such mean scores to
inform possible sensitivity analysis to be used in other stud-
ies that may be using their results. So far, there are no evi-
dences indicating that researchers are providing information
on the approaches they used with regard to the ‘time-effect’
in the calculation of QALYs from preference-based utility
values collected at different time-points along clinical trials.
Conclusion
Quality-adjusted life years are prominent yardsticks in eco-
nomic evaluation of healthcare interventions in the United
Kingdom. QALYs are in fact the recommended measure of
disease burden by NICE.[11] The most frequently used
health-related quality of life instrument in the estimation of
QALYs has been EuroQol’s EQ-5D instrument.[12] The esti-
mation of QALYs in this prospective clinical trial was
based on EQ-5D-3L which was collected at speciﬁc time-
points.
Quality-adjusted life years are a product of health utili-
ties and the ‘time’ a person spent in that health utilities
state. This therefore explains the possible impact the ‘time-
effect’ can have on QALY estimations along prospective
clinical trials where utility values are collected at speciﬁc
time-points.
That time component in QALY estimations can be calcu-
lated using the exact dates on patient records, that is the
dates the utility values were taken or just using the same
assumed time for all the participants. Using paired-sample t-
test, this study reveals statistically signiﬁcant difference
between the two approaches demonstrating the potential
impact the ‘time-effect’ can therefore have on trial results
both in terms of QALYs and the attendant cost-effective-
ness. The cost-effectiveness ratio was £93 504.09/QALY
using actual time period approach in calculation of QALYs.
When the ﬁxed-period approach was used, the cost-effec-
tiveness ratio increased to £119 575.83/QALY. This result
does not only justify the need for researchers to pay due
considerations to the approach they used in QALY
estimations, but most importantly, it emphasises the need
for researchers to use actual time durations in QALY esti-
mations along prospective clinical trials.
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